文献速递骨肿瘤关节外科

肱骨近端肿瘤:高限制性反式全肩关节置换翻修风险高于预期

Proximal Humerus Tumors: Higher-than-Expected Risk of Revision With Constrained Reverse Shoulder Arthroplasty.
PubMed 文献 · Clin Orthop Relat Res · 2020-01-01

本研究回顾性分析了18例因肱骨近端恶性肿瘤行高限制性反式全肩关节置换的患者,最终14例随访至少2年。中位随访35个月时,MSTS评分中位78%,DASH评分20,Constant-Murley评分53%,翻修累积发生率为18%(95%CI 2-45),无脱位发生。作者警告高限制性设计可能将不稳定性风险转化为无菌性松动风险。

要点

  • 高限制性反式全肩关节置换术后翻修累积发生率为18%(95%CI 2-45),高于其他肱骨近端假体报道。
  • 中位随访35个月时未发生脱位,但高限制性设计可能增加假体-骨界面应力导致松动。
  • 功能结果:MSTS评分中位78%,Constant-Murley评分53%,DASH评分20。

核心结论

  • 高限制性反式全肩关节假体在肱骨近端肿瘤切除重建中翻修风险高于其他假体的既往报道。
  • 高限制性设计在预防不稳定的同时可能将应力传导至假体-骨界面,导致无菌性松动。
  • 作者认为类似限制程度的其他假体可能面临同样问题,改变患者选择指征可能无法解决。

研究设计与样本

  • 回顾性研究,2014年1月至2017年6月共55例肱骨近端恶性肿瘤切除重建患者,其中18例(33%)使用研究中的高限制性反式全肩关节假体。
  • 18例中4例死亡(3例假体完好),无患者在2年前失访,最终14例(7女7男)纳入分析,中位随访35个月(范围25-65)。
  • 采用竞争风险分析(以死亡为竞争事件)估计翻修累积发生率,翻修定义为因任何原因取出或更换假体的再手术。

主要发现

  • 末次随访时MSTS评分中位78%(范围50-90),DASH评分中位20(范围8-65),Constant-Murley评分中位53%(范围26-83)。
  • 中位活动度:前屈75°(40-160),外展78°(30-150),内旋35°(10-80),外旋33°(0-55)。
  • 14例中2例发生或计划进行翻修手术,30个月和48个月翻修累积发生率均为18%(95%CI 2-45)。
  • 研究期间无患者报告不稳定,无脱位发生。

关键数值与推荐

  • 研究中使用高限制性假体的指征为:肿瘤侵犯需切除三角肌/腋神经或三角肌肱骨止点,或广泛肩袖及周围软组织切除可能导致肩关节不稳定。
  • MSTS评分范围0%-100%,越高功能越好;Constant-Murley评分范围0%-100%,越高功能越好;DASH评分范围0-100分,越高残疾越重。
  • 影像学松动定义为随访间进行性透亮线、假体组件移位、骨水泥碎裂/骨折;肩胛骨切迹采用Sirveaux分类。

临床怎么用

  • 对于肱骨近端肿瘤需广泛软组织切除的高不稳定风险患者,高限制性反式全肩关节假体可预防脱位,但需警惕无菌性松动的翻修风险。
  • 术后随访应关注影像学松动迹象,包括进行性透亮线、组件移位和骨水泥碎裂。
  • 与患者沟通时需权衡不稳定性与无菌性松动的风险交换。

局限性

  • 样本量小(最终仅14例分析),随访时间短(中位35个月)。
  • 为回顾性研究,证据等级为Level IV(治疗性研究)。
  • 高限制性设计增加假体-骨界面应力导致松动的理论需生物力学研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment of proximal humerus tumors with endoprostheses is associated with a high risk of implant-related surgical complications. Because of extensive soft-tissue resection and muscular detachment during surgery, instability is the most common serious complication. A reverse total shoulder arthroplasty with a highly constrained design is one option to mitigate instability, but few studies have reported the results of this prosthesis for proximal humerus tumor resections. QUESTIONS/PURPOSES: (1) What are the short-term functional results of the constrained reverse total shoulder prosthesis in terms of Musculoskeletal Tumor Society (MSTS), DASH, and Constant-Murley scores and ROM values? (2) What is the frequency of revision, using a competing-risks estimator to assess implant survival, and what were the causes of the revisions that occurred? (3) What proportion of patients experienced dislocations at short-term follow-up? METHODS: Between January 2014 and June 2017, we treated 55 patients with proximal humeral resections and reconstructions for malignant tumors. Of those, 33% (18) of patients were treated with the constrained, reverse total shoulder arthroplasty implant under study here. During that period, no other constrained reverse total shoulder implant was used; however, 13% (seven) of patients were treated with conventional (unconstrained) reverse total shoulder implants, 27% (15) had hemiarthroplasties, 15% (eight) of patients had biologic reconstructions with auto- or allografts and 13% (seven) underwent amputation. During the period in question, our general indications for use of the constrained device under study here were resection of the deltoid muscle/axillary nerve or the deltoid insertion on the humerus due to tumor invasion, or extensive rotator cuff and surrounding soft tissue resection that might result in shoulder instability. During this period, these indications were adhered to consistently. Four of 18 patients treated with the study implant died (three died with the implant intact) and none were lost to follow-up before 2 years, leaving 14 patients (seven women and seven men) for study at a median (range) follow-up of 35 months (25 to 65). Two authors evaluated the clinical and functional status of each patient with ROM (flexion, extension, internal and external rotation, abduction, and adduction) and MSTS, (range 0% to 100%), Constant-Murley (range 0% to 100%), and DASH (range 0 points to 100 points) scores. For the MSTS and Constant-Murley scores, higher percentage scores mean better functional outcome; and for the DASH score, a higher score means more severe disability. Radiographs were obtained at each visit and were used to look for signs of loosening, which we defined as progressive radiolucencies between visits, prosthetic component migration, and fragmentation/fracture of the cement. The Sirveaux classification was used to determine scapular notching. A competing risks analysis with 95% confidence intervals was performed to estimate the cumulative incidence of revision surgery, which we defined as any reoperation in which the implant was removed or changed for any reason, with patient mortality as a competing event. RESULTS: At the most recent follow-up, the median (range) MSTS score was 78% (50 to 90), the DASH score was 20 (8 to 65), and the Constant-Murley score was 53% (26 to 83). The median ROM was 75° in forward flexion (40 to 160), 78° in abduction (30 to 150), 35° in internal rotation (10 to 80), and 33° in external rotation (0 to 55). Postoperatively, two of 14 patients underwent or were supposed to undergo revision surgery, and the cumulative incidence of revision surgery was 18% for both 30 and 48 months (95% CI 2 to 45). During the study period, no patients reported instability, and no dislocations occurred. CONCLUSIONS: Our findings are concerning because the revision risk with this constrained reverse total shoulder implant was higher than has been reported by others for other proximal humerus prostheses. The highly constrained design that helps prevent instability might also transmit increased stresses to the humeral component-bone interface, therefore making it susceptible to loosening. We believe that any other implant with a similar degree of constraint will have the same problem, and changing the indications for patient selection may not solve this issue. These theories need to be tested biomechanically, but our desire is to warn surgeons that while trying to prevent instability, one might trade one complication (instability) for another: aseptic loosening. LEVEL OF EVIDENCE: Level IV, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Ayvaz M, Cetik RM, Bakircioglu S, et al. Proximal Humerus Tumors: Higher-than-Expected Risk of Revision With Constrained Reverse Shoulder Arthroplasty. Clin Orthop Relat Res. 2020. PMID: 32281773. doi:10.1097/CORR.0000000000001245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。